31results about How to "Inhibition of degranulation" patented technology

The invention discloses application of phenolic compounds. The phenolic compounds are shown in the formulas (I)-(III). The phenolic compounds are used for preparing anti-allergic drugs. Through research, it is found that the three phenolic compounds have strong inhibition effects on degranulation of mast cells, and can be used for preparing anti-allergic drugs, especially anti-food-allergy drugs;through fermentation of deep-sea fungi, namely penicillium chrysanthum which has rich sources, the three substances with strong anti allergic activity are obtained at the same time, compared with directional synthesis during which a variety of by-products are produced, the preparation method is more suitable for industrial production and natural resources are rationally utilized.

The invention discloses a method for preparing atomized liquid for treating infantile asthmatic suffocating pneumonia. The atomized liquid comprises gleditsia fruit, loquat leaf, European hop flower, Chinese waxgourd semen, common bluebeard herb, platycodon root, red clover, whiteflower hogfennel root and borneol which serve as raw materials. The method is characterized by comprising the following steps of: (1) extracting the loquat leaf, the European hop flower and the common bluebeard herb by a supercritical fluid extraction method to obtain volatile oil; (2) crushing the gleditsia fruit and the borneol into superfine powder; (3) decocting the red clover, the whiteflower hogfennel root, the Chinese waxgourd semen and the platycodon root in water twice, filtering, mixing filtrates, and concentrating at the temperature of 80 DEG C until the relative density is 1.1 to obtain a water extracting solution; and (4) stirring the volatile oil obtained in the step (1), the superfine powder obtained in the step (2) and the water extracting solution obtained in the step (3) uniformly, standing at normal temperature for 12 hours, and filtering to obtain liquid medicine. Clinical experiments prove that the atomized liquid prepared by the method has an obvious treatment effect, and the hospital stays can be shortened.

The invention relates to the biotechnology field, and more specifically, the invention discloses a human monoclonal antibody against IgE, a preparation method and a purpose thereof. According to the invention, a natural human phage antibody library of large capacity is constructed;; a human antibody 2E19 strain against IgE is obtained through screening from the library; an amino acid sequence of a heavy chain variable region is expressed as SEQ ID NO: 6; and the amino acid sequence of a light chain variable region is expressed as SEQ ID NO: 8. Besides, the invention also discloses the preparation method of the antibody 2E19, as well as a nucleotide sequence for encoding the antibody 2E19 and an expression vector and a host cell comprising the nucleotide sequence. The antibody 2E19 of the invention has a higher antibody affinity, so as to be able to obviously inhibit degranulation caused by the combination of IgE and FC epsilon RI on a cell surface, and the antibody 2E19 does not combine with the IgE combined with the FC epsilon RI on the cell surface. The antibody 2E19 of the invention could be used for the preparation of a medicine for treating hypersensitivity diseases, especially for treating allergic asthma.

The invention discloses application of IL-1ra-Fcepsilon fusion gene and coded protein thereof to treatment on allergic rhinitis, belonging to the field of medicines. In the invention, the constructed IL-1ra-Fcepsilon fusion gene expression vector is prepared into suspension according to a certain concentration and the suspension is directly dropped into a nasal cavity to treat the allergic rhinitis; or the purified IL-1ra-Fcepsilon fusion gene is diluted to a certain concentration with a PBS (Phosphate Buffered Saline) buffer solution and then the diluted solution is dropped into the nasal cavity to treat the allergic rhinitis. In the invention, the protein coded by the IL-1ra-Fcepsilon fusion gene can antagonize the inflammatory effect of IL-1 and inhibit mastocyte and basophilic granulocyte degranulation, thereby achieving the aim of treating the allergic rhinitis.

The invention relates to an application of notoginsenoside for treating septicemia, particularly relates to ginsenoside Rb1 which is the effective component of notoginsenoside, and an application of ginsenoside Rb1 and notoginsenoside R1 in treating and / or preventing septicemia.

The invention discloses a traditional-Chinese-medicine active compound with the Syk inhibitory activity and its preparation method and application. It is found that the active compound, namely ginkgolic acid C15:1 or ginkgolic acid C13:0, has the spleen tyrosine kinase (Syk) inhibition activity, research further shows that the active compound has the effect of inhibiting mastocyte degranulation, the traditional-Chinese-medicine active compound ginkgolic acid C15:1 is obtained from ginkgo medicinal materials for the first time, and it is verified that the traditional-Chinese-medicine active compound ginkgolic acid C15:1 has the Syk inhibition activity and the mastocyte degranulation inhibition activity. The effective component and chemical component of the active compound ginkgolic acid C15:1 or ginkgolic acid C13:0 are simple, the action target is clear, the Syk activity can be directly inhibited, the mastocyte degranulation is inhibited, the action mechanism of the ginkgolic acid C15:1 or ginkgolic acid C13:0 is easier to illuminate in pharmacological research, and the ginkgolic acid has a potential application value in the prevention and treatment of allergic asthma and provides a new medicine selection for the prevention and treatment of allergic asthma.

The invention belongs to the technical field of biotechnology and relates to a human IgE (immunoglobulin E) Fab (fragment ab) against human and a coding gene and application thereof. In the invention, a recombined IgE C3-C4 protein is used for screening a natural human immunoglobulin gene library, and a human antibody Fab of IgE against human is screened from the library through ELISA (enzyme-linked immunosorbent assay) sequencing analysis and the like; extensive expression purification and further identification prove that the antibody Fab of human IgE against human is fully human and without Fc (fragment c), has an effect of inhibiting IgE mediated anaphylaxis without activating complements or causing human immune response or other pathological lesions and can be used for preparing antibody drugs for treating allergic diseases caused by IgE.

The invention discloses a medicinal composition for treating child asthmatic suffocating pneumonia. The medicinal composition is characterized by being processed from multiple Chinese medicines in parts by weight: 1-3 parts of Chinese honey locust, 6-9 parts of loguat leaf, 10-15 parts of european hop flower, 10-15 parts of waxgourd seed, 6-9 parts of common bluebeard herb, 6-9 parts of platycodon root, 10-15 parts of red clover flower and inflorescence, 6-9 parts of whiteflower hogfennel root and 1-3 parts of borneol. As proved by clinical experiments, the medicinal composition for treating child asthmatic suffocating pneumonia has the characteristics of good curative effect and high safety, and is worthy of clinical application and popularization.

The present invention relates to the technical field related to the extraction of pure natural woody plants, more specifically, the present invention provides a pure natural woody plant extract and its application. The first aspect of the present invention provides a kind of preparation method of pure natural woody plant extract, comprises the following steps: (1) green tea is added into pure water, then boils; Keep the distillate. The invention provides an extraction method of a pure natural single woody plant that can be used as a soothing agent. The obtained plant extract is light in color, not turbid, stable in storage, and has a delicate fragrance; it is non-toxic and non-irritating to the skin; and it can inhibit hypertrophy Cell degranulation phenomenon, with soothing effect.

The invention relates to novel application of a Chaenomeles speciosa (sweet) Nakai extract, specifically to application of oleanolic acid, ursolic acid, oleanolic saponins and ursolic saponins in the extract in the pharmaceutical field. The extract has effects on inhibition of DNP-BSA induced RBL-2H3 mast cell degranulation, DNP-BSA induced mBMMCs mast cell degranulation, calcium ionophore A23187 induced RBL-2H3 mast cell degranulation and Thapsigargin induced RBL-2H3 mast cell degranulation and on xylene-induced acute inflammation like ear swelling of mice and has a high medicinal value.

The invention discloses the application of a compound in the preparation of antiallergic medicine, characterized in that the molecular formula of the compound is C 29 H 27 NO 8 , its chemical structural formula is: the present invention finds that the compound T-5224 can significantly inhibit the release of β-aminoglycosidase in mast cells, has the effect of significantly inhibiting the degranulation of mast cells, and can significantly inhibit allergy in mice reaction. This fully shows that the T-5224 compound can be used to prepare antiallergic drugs and has broad application prospects.